9 terminated. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Terminated 9 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib Famitinib capsules, Sunitinib Capsules - Gastrointestinal Stromal Tumors | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 185 | 2020-09-12 | 2024-02-09 |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) bempegaldesleukin, sunitinib, nivolumab - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | Terminated | Nektar Therapeutics | 623 | 2018-12-18 | 2023-04-11 |
| Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery sunitinib or pazopanib, Cytoreductive nephrectomy - Clear-cell Metastatic Renal Cell Carcinoma | Phase 3 | Terminated | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 13 | 2015-11-01 | 2018-11-14 |
| Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma Standard Treatment, AGS-003 - Advanced Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 3 | Terminated | Argos Therapeutics | 462 | 2012-11-01 | 2018-06-14 |
| Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer sunitinib malate, sorafenib - Carcinoma, Hepatocellular | Phase 3 | Terminated | Pfizer | 1075 | 2008-07-01 | 2013-01-14 |
| Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy Prednisone, sunitinib, Placebo - Prostatic Neoplasms | Phase 3 | Terminated | Pfizer | 873 | 2008-07-01 | 2013-03-08 |
| A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors sunitinib malate, Placebo - Carcinoma, Islet Cell, Carcinoma, Pancreas | Phase 3 | Terminated | Pfizer | 171 | 2007-06-01 | 2010-10-11 |
| Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors sunitinib malate, imatinib mesylate - Gastrointestinal Stromal Tumor | Phase 3 | Terminated | Pfizer | 69 | 2007-06-01 | 2011-03-17 |
| A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine Capecitabine, Sunitinib malate - Breast Neoplasms | Phase 3 | Terminated | Pfizer | 482 | 2006-11-01 | 2012-06-25 |
Carcinoma, Renal Cell (2) · Gastrointestinal Stromal Tumors (2) · Kidney Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Islet Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Pfizer (5) · Argos Therapeutics (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Nektar Therapeutics (1)
Italy (7) · Spain (6) · United Kingdom (6) · United States (6) · Australia (5) · Canada (5) · Germany (5) · South Korea (5) · France (4) · Taiwan (4) · Belgium (3) · Brazil (3) · China (3) · Hong Kong (3) · Peru (3)
Christopher G Wood, MD, FACP (1) · Giuseppe Procopio, MD (1) · Jianming Xu, MD (1) · Robert Figlin, MD, FACP (1)
PMID 20203173, PMID 21306237, PMID 24081937, PMID 24323035, PMID 27836885, PMID 27924459, PMID 29161241, PMID 32034074, PMID 32203306, PMID 33411058, PMID 35226112, PMID 38838287
2015 (1)